A CBD product sold in the United Kingdom qualifies as an “exempt product” under the Misuse of Drugs Regulations 2001 only if it meets all three CBD exempt product criteria in Regulation 2(1): it is not designed for the administration of a controlled drug, its controlled cannabinoids cannot be recovered by readily applicable means in a quantity that poses a health risk, and no single component part contains more than one milligram of any controlled drug.1GOV.UK. Letter From the ACMD Advising on the Exempt Product Definition in the Misuse of Drugs Regulations 2001 Fail any one of the three, and the product is treated as a controlled substance, with criminal liability running through the supply chain.
Which Cannabinoids the Test Covers
Cannabidiol itself is not a controlled substance. The hemp extracts used to make CBD products almost always are, in trace amounts, because Schedule 2, Part II of the Misuse of Drugs Act 1971 lists cannabinol, cannabinol derivatives, and cannabis resin as Class B drugs.2Legislation.gov.uk. Misuse of Drugs Act 1971, Schedule 2 The definition of cannabinol derivatives in Part IV of that schedule covers tetrahydro derivatives of cannabinol, which pulls in both THC and THCV. So the three controlled cannabinoids that decide exempt status are THC, THCV, and CBN.
The stakes are why the classification matters. Possession of a Class B drug without authorisation carries up to five years in prison, an unlimited fine, or both.3GOV.UK. Drugs Penalties Supply or intent to supply carries up to 14 years. Those penalties apply to consumers who bought a non-compliant product and to retailers who stocked one.
Limb One: Not Designed to Administer a Controlled Drug
The product must not be designed to administer a controlled drug to a person or animal. In practice, the purpose of a CBD oil, capsule, or topical cannot be to deliver THC, THCV, or CBN for their pharmacological effects. A product formulated and marketed so that any controlled cannabinoid content is incidental to the CBD content will normally satisfy this limb. A product that highlights or relies on its THC content will not.
Limb Two: Not Recoverable by Readily Applicable Means
The controlled cannabinoids must be packaged or combined with other substances in a way that prevents someone from extracting them using simple methods in a quantity that poses a health risk.1GOV.UK. Letter From the ACMD Advising on the Exempt Product Definition in the Misuse of Drugs Regulations 2001 If a person could isolate THC with basic kitchen equipment or a straightforward filtration technique and end up with enough material to produce a psychoactive effect, the product fails. This limb looks at the physical and chemical nature of the formulation, not the total quantity in the container.
Limb Three: One Milligram Per Component Part
No single component part of the product may contain more than one milligram of a controlled drug.1GOV.UK. Letter From the ACMD Advising on the Exempt Product Definition in the Misuse of Drugs Regulations 2001 The Home Office has stated that the relevant component part is the container itself, such as a bottle of oil, not a supposed typical dose.4GOV.UK. Drug Licensing Factsheet: Cannabis, CBD and Other Cannabinoids This is an absolute weight limit rather than a percentage, so a 100ml bottle and a 10ml vial answer to the same standard.
The rule catches businesses out in two ways. If a bottle of CBD oil contains 1.1mg of THC, it fails, no matter how much total liquid sits in the bottle or how little THC any single serving delivers. And splitting a non-compliant batch into smaller retail units doesn’t fix the problem, because the smallest individual retail container is the component part being measured. The 1mg ceiling also applies to each controlled cannabinoid the product contains, so THC, THCV, and CBN each need to be counted and each need to stay under the limit.
Proving It: The Certificate of Analysis
Meeting the three-limb test on paper counts for nothing without evidence. That evidence takes the form of a Certificate of Analysis from an independent laboratory that quantifies each controlled cannabinoid in the finished product. Labs with ISO/IEC 17025 accreditation are the standard expectation, because their results carry weight in enforcement proceedings.
The analytical method matters as much as the number on the certificate. Gas chromatography uses high temperatures that cause the acidic precursor forms of cannabinoids (THCA and CBDA) to convert into their neutral forms (THC and CBD) during the test itself. A GC result therefore reports “total THC,” combining THC that was already present with THC created by the testing process. Liquid chromatography runs at lower temperatures and can separately quantify the acidic and neutral forms, giving a more precise picture of what a consumer would actually ingest without heating the product. For products consumed orally at room temperature, liquid chromatography reflects the controlled cannabinoid content as it exists in the container.
A useful test report specifies the method used, states the limit of detection, and gives a separate figure for THC, THCV, and CBN. Without that documentation, a distributor has no defence if enforcement authorities question whether the product is a controlled substance.
What Happens If a Product Fails
A product that misses any limb of the exempt test is a controlled substance in the eyes of the law, and handling it requires a controlled drug licence from the Home Office. The licence type depends on the activity, and fees run from £3,133 for possession only up to £4,700 for producing controlled drugs.5GOV.UK. Controlled Drugs and Precursor Chemicals: Licence Fees After an application is submitted, the Home Office typically conducts a compliance visit to inspect the physical security of the premises and record-keeping systems.4GOV.UK. Drug Licensing Factsheet: Cannabis, CBD and Other Cannabinoids Operating without the right licence while holding controlled substances can lead to prosecution and seizure of inventory. Most retail CBD businesses avoid that route by ensuring finished products qualify as exempt before they ever take delivery.
What Exempt Status Does Not Cover
Clearing the three-limb test resolves the controlled drug question and nothing else. Two other regimes sit alongside it, and a compliant product can still be unlawful to sell if either is ignored.
Orally consumed CBD products (oils, capsules, gummies, drinks) are classed as novel foods by the Food Standards Agency and must appear on the FSA’s public list of CBD products linked to validated novel food applications.6Food Standards Agency. CBD Products Linked to Novel Food Applications Products absent from the list, or marked “Removed,” must be withdrawn.
Separately, the Medicines and Healthcare products Regulatory Agency treats any CBD product marketed with a medicinal claim as an unlicensed medicine.7GOV.UK. MHRA Statement on Products Containing Cannabidiol (CBD) A statement that a product “reduces anxiety,” “relieves chronic pain,” or “helps with insomnia” is enough to trigger classification as a medicinal product under the Human Medicines Regulations 2012, at which point a Marketing Authorisation is required before it can be sold, supplied, or advertised. A product that passes the exempt test and sits on the FSA novel food list can still face enforcement action on the strength of its packaging or website copy alone.